methyl 2-isocyanatosulfonylbenzoate

We are methyl 2-isocyanatosulfonylbenzoate CAS:74222-95-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 74222-95-0
Product Name: methyl 2-isocyanatosulfonylbenzoate
Other Name:
methyl 2-isocyanatosulfonylbenzoate
2-carbomethoxyphenylsulfonyl isocyanate
2-carbomethoxybenzenesulfonyl isocyanate
2-carboxymethylsulfonyl isocyanate
o-methoxycarbonylbenzenesulfonyl isocyanate
Methyl 2-[(oxomethylene)sulfamoyl]benzoate
2-(Isocyanatosulfonyl)benzoic acid methyl ester
 
Density: 1.4±0.1 g/cm3
Boiling Point: 362.0±25.0 °C at 760 mmHg
Molecular Formula: C9H7NO5S
Molecular Weight: 241.221
Flash Point: 172.7±23.2 °C
Exact Mass: 241.004486
PSA: 98.25000
LogP: 1.95
Vapour Pressure: 0.0±0.8 mmHg at 25°C
Index of Refraction: 1.570
 
Specification
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Ethametsulfuron-Methyl CAS: 97780-06-8.
Intermediates of Sulfometuron-Methyl CAS: 74222-97-2.
Intermediates of Metsulfuron-Methyl CAS: 74223-64-6.
Be used as pesticide intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

methyl 2-isocyanatosulfonylbenzoate


Related News: Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’.3-Bromo-2-fluoro-5-nitropyridine CAS:1868-58-2 Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’.Ácido 3- (4-clorofenil) glutámico CAS:1141-23-7 Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined.3-Chloropropyne CAS:624-65-7 Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.Commonly used generic drugs: the products whose patents have expired and the generic drugs of many companies have participated in the competition, and the market demand is large.

Related Products
Product Name
phenethyl isothiocyanate View Details
View Details
(2E,4E)-2,4-Octadienal View Details
L-Glutamine manufacturer 2-Bromo-3-nitro-4-picoline manufacturer 2-Furoyl chloride manufacturer 4-Bromoveratrole manufacturer 3-Methyl-3-Pyrazolin-5-One manufacturer